Study to Evaluate the Pharmacokinetics & Food Effect of MK-0941 in Adults With Type 2 Diabetes (MK-0941-009)
Primary Purpose
Type 2 Diabetes Mellitus
Status
Completed
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
10 mg MK-0941 DFC (fasted)
10 mg MK-0941 OCT (after meal)
10 mg MK-0941 OCT (before meal)
10 mg MK-0941 OCT (fasted)
Sponsored by

About this trial
This is an interventional treatment trial for Type 2 Diabetes Mellitus
Eligibility Criteria
Inclusion Criteria:
- Males or females (of non-childbearing potential) between the ages of 18 to 70
- Participants have been diagnosed with Type 2 Diabetes
- Participants are nonsmokers for at least 6 months
Exclusion Criteria:
- Participant should not be diagnosed with Type 1 diabetes
- Participant should not be receiving insulin or PPAR gamma agonists for 12 weeks prior to study start
- Participant has a recent history of eye infection or other inflammatory eye condition within 2 weeks prior to study start
- Participant has been diagnosed with glaucoma or is blind
- Participant has had trauma to one or both eyes
- Participant has had major surgery, donated blood or participated in another clinical study in the past 4 weeks
- Participant is a regular user of illicit drugs or has a history of drug, including alcohol, abuse in the past 6 months
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm Type
Experimental
Experimental
Experimental
Active Comparator
Arm Label
DFC (fasted)
OCT (fasted)
OCT (after meal)
OCT (before meal)
Arm Description
Outcomes
Primary Outcome Measures
Area Under the Curve (AUC)(0-∞) for Oral Compressed Tablet (OCT) (Fasted) and Dry Filled Capsule (DFC) (Fasted)
Maximum Concentration (Cmax) for OCT (Fasted) and DFC (Fasted)
Time to Reach Cmax (Tmax) for OCT (Fasted) and DFC (Fasted)
Half Life (t½) for OCT (Fasted) and DFC (Fasted)
Secondary Outcome Measures
AUC(0-∞) for OCT (Fasted) and OCT (After Meal)
Cmax of OCT (Fasted) and OCT (After Meal)
Tmax for OCT (Fasted) and OCT (After Meal)
t1/2 for OCT (Fasted) and OCT (After Meal)
Full Information
NCT ID
NCT00567112
First Posted
November 30, 2007
Last Updated
March 12, 2015
Sponsor
Merck Sharp & Dohme LLC
1. Study Identification
Unique Protocol Identification Number
NCT00567112
Brief Title
Study to Evaluate the Pharmacokinetics & Food Effect of MK-0941 in Adults With Type 2 Diabetes (MK-0941-009)
Official Title
An Open-Label, Randomized, Partially Fixed-Sequence, 4-Period Crossover Study to Assess the Pharmacokinetics After Administration of the DFC and OCT Formulations and the Food Effect on the OCT Formulation of MK-0941 in Patients With Type 2 Diabetes
Study Type
Interventional
2. Study Status
Record Verification Date
March 2015
Overall Recruitment Status
Completed
Study Start Date
November 2007 (undefined)
Primary Completion Date
February 2008 (Actual)
Study Completion Date
April 2008 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Merck Sharp & Dohme LLC
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
A study to compare the pharmacokinetics (PK) of the dry filled capsule (DFC) & oral compressed tablet (OCT) formulations of MK-0941-009 & to assess the effect of food on the OCT formulation.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
18 (Actual)
8. Arms, Groups, and Interventions
Arm Title
DFC (fasted)
Arm Type
Experimental
Arm Title
OCT (fasted)
Arm Type
Experimental
Arm Title
OCT (after meal)
Arm Type
Experimental
Arm Title
OCT (before meal)
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
10 mg MK-0941 DFC (fasted)
Intervention Description
single dose of 10 mg MK-0941 dry filled capsules (DFC) administered in a fasted state
Intervention Type
Drug
Intervention Name(s)
10 mg MK-0941 OCT (after meal)
Intervention Description
single dose of 10 mg MK-0941 oral compressed tablet (OCT) administered after consumption of a high-fat meal
Intervention Type
Drug
Intervention Name(s)
10 mg MK-0941 OCT (before meal)
Intervention Description
single dose of 10 mg MK-0941 oral compressed tablet (OCT) administered before consumption of a standard breakfast
Intervention Type
Drug
Intervention Name(s)
10 mg MK-0941 OCT (fasted)
Intervention Description
single dose of 10 mg MK-0941 oral compressed tablet (OCT) administered in a fasted state
Primary Outcome Measure Information:
Title
Area Under the Curve (AUC)(0-∞) for Oral Compressed Tablet (OCT) (Fasted) and Dry Filled Capsule (DFC) (Fasted)
Time Frame
From study drug administration to 72 hours post-administration
Title
Maximum Concentration (Cmax) for OCT (Fasted) and DFC (Fasted)
Time Frame
From study drug administration to 72 hours post-administration
Title
Time to Reach Cmax (Tmax) for OCT (Fasted) and DFC (Fasted)
Time Frame
From study drug administration to 72 hours post-administration
Title
Half Life (t½) for OCT (Fasted) and DFC (Fasted)
Time Frame
From study drug administration to 72 hours post-administration
Secondary Outcome Measure Information:
Title
AUC(0-∞) for OCT (Fasted) and OCT (After Meal)
Time Frame
From study drug administration to 72 hours post-administration
Title
Cmax of OCT (Fasted) and OCT (After Meal)
Time Frame
From study drug administration to 72 hours post-administration
Title
Tmax for OCT (Fasted) and OCT (After Meal)
Time Frame
From study drug administration to 72 hours post-administration
Title
t1/2 for OCT (Fasted) and OCT (After Meal)
Time Frame
From study drug administration to 72 hours post-administration
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Males or females (of non-childbearing potential) between the ages of 18 to 70
Participants have been diagnosed with Type 2 Diabetes
Participants are nonsmokers for at least 6 months
Exclusion Criteria:
Participant should not be diagnosed with Type 1 diabetes
Participant should not be receiving insulin or PPAR gamma agonists for 12 weeks prior to study start
Participant has a recent history of eye infection or other inflammatory eye condition within 2 weeks prior to study start
Participant has been diagnosed with glaucoma or is blind
Participant has had trauma to one or both eyes
Participant has had major surgery, donated blood or participated in another clinical study in the past 4 weeks
Participant is a regular user of illicit drugs or has a history of drug, including alcohol, abuse in the past 6 months
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Medical Monitor
Organizational Affiliation
Merck Sharp & Dohme LLC
Official's Role
Study Director
12. IPD Sharing Statement
Learn more about this trial
Study to Evaluate the Pharmacokinetics & Food Effect of MK-0941 in Adults With Type 2 Diabetes (MK-0941-009)
We'll reach out to this number within 24 hrs